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Abstract
Protein ubiquitination is a critical regulator of cellular homeostasis. Aberrations in the addition or removal of ubiquitin can
result in the development of cancer and key components of the ubiquitination machinery serve as oncogenes or tumour
suppressors. An emerging target in the development of cancer therapeutics are the deubiquitinase (DUB) enzymes that
remove ubiquitin from protein substrates. Whether this class of enzyme plays a role in cervical cancer has not been fully
explored. By interrogating the cervical cancer data from the TCGA consortium, we noted that the DUB USP13 is amplified
in ~15% of cervical cancer cases. We confirmed that USP13 expression was increased in cervical cancer cell lines, cytology
samples from patients with cervical disease and in cervical cancer tissue. Depletion of USP13 inhibited cervical cancer cell
proliferation. Mechanistically, USP13 bound to, deubiquitinated and stabilised Mcl-1, a pivotal member of the anti-apoptotic
BCL-2 family. Furthermore, reduced Mcl-1 expression partially contributed to the observed proliferative defect in USP13
depleted cells. Importantly, the expression of USP13 and Mcl-1 proteins correlated in cervical cancer tissue. Finally, we
demonstrated that depletion of USP13 expression or inhibition of USP13 enzymatic activity increased the sensitivity of
cervical cancer cells to the BH3 mimetic inhibitor ABT-263. Together, our data demonstrates that USP13 is a potential
oncogene in cervical cancer that functions to stabilise the pro-survival protein Mcl-1, offering a potential therapeutic target
for these cancers.
Introduction
Protein ubiquitination is a critical post-translation mod-
ification that is essential for the regulation of cellular
homeostasis [1]. The process of ubiquitination occurs
through a stepwise enzymatic cascade comprising three
classes of enzymes: E1 ubiquitin-activating enzymes, E2
ubiquitin-conjugating enzymes and E3 ubiquitin ligases.
The functional outcome of protein ubiquitination is depen-
dent on the type of modification (monoubiquitin or poly-
ubiquitin) and the linkage type within the ubiquitin chain
[2]. This diversity of potential ubiquitin signals is able to
regulate a wide range of cellular processes. For example,
K48 or K11 polyubiquitin chains are primarily responsible
for promoting protein degradation, whereas chains linked
by M1 or K63 polyubiquitin direct the assembly of protein
complexes to regulate signal transduction [3]. Conse-
quently, the deregulation of protein ubiquitination can result
in the promotion of diseases including cancer. For example,
defects in ubiquitin-mediated proteasomal degradation can
result in either the enhanced degradation of tumour sup-
pressor proteins, or in the stabilisation of oncogenes [4].
Ubiquitination is a highly dynamic and reversible post-
translational modification, and deubiquitinase enzymes
(DUBs) readily cleave ubiquitin from its protein substrates
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[5]. To date, over 100 DUBs have been identified in the
human genome that are classified into seven families on the
basis of the catalytic mechanism and structural similarity;
members of the ubiquitin C-terminal hydrolases (UCHs),
ubiquitin-specific proteases (USPs), ovarian tumour pro-
teases (OTUs), the Machado-Josephin domain superfamily
(MJD), the MINDY family and the ZUFSP family function
as cysteine proteases, whereas JAB1/MPN/MOV34 metal-
loenzymes (JAMMs) are zinc-dependent metalloproteases
[5]. In the last 10 years, DUBs have been shown to regulate
the actions of proteins involved in cancer progression,
including the tumour suppressors p53 and PTEN, and the
oncogenes c-Myc and EGFR [6–9]. Therefore, the phar-
macological targeting of DUBs offers a potential ther-
apeutic opportunity for treating cancers [4]. For example,
FT671 is a highly specific, non-covalent small molecule
inhibitor of USP7, a DUB that regulates MDM2 levels, a
critical negative regulator of the p53 tumour suppressor
[10, 11]. FT671 efficiently destabilised MDM2 in Multiple
Myeloid MM.1s cells, resulting in increased p53 expression
and inhibiting tumour growth in murine xenografts [11].
Cervical cancer is the fourth most common cancer in
women, causing significant morbidity and mortality
worldwide [12]. Persistent infection with human papillo-
mavirus (HPV) is the underlying cause of almost all cervical
cancers, with the high-risk (HR) HPV16 and HPV18 types
being the two most prevalent HPV types responsible [13].
HPV-induced transformation is primarily driven by the E6
and E7 viral oncogenes [14, 15], and this is achieved
through the extensive manipulation of host cell signalling
networks [16–21]. Critically, E6 and E7 promote the pro-
teasomal degradation of the p53 and pRb tumour sup-
pressors, by co-opting the E3 ligases E6-associated protein
(E6-AP) and a Cullin-2 ubiquitin ligase complex [22–24].
In addition, the minor HPV oncoprotein E5 can enhance
EGFR signalling [25–28], in part by disrupting the c-Cbl/
EGFR complex, thereby decreasing c-Cbl-mediated ubi-
quitination and degradation of the EGFR [29]. Several
DUBs are also targeted during the HPV life cycle and in
HPV-associated cancers [30–33]. These data suggest that
the deregulation of protein ubiquitination plays a key role in
HPV associated cancers. To identify novel DUBs involved
in cervical cancer progression, we interrogated the cervical
cancer data from the TCGA consortium. We identified that
USP13 is amplified in about 15% of cervical cancer cases.
We further demonstrated that USP13 was required for the
proliferation of HPV positive cervical cancer cells, at least
in part via the deubiquitination and stabilisation of the pro-
survival protein, Mcl-1. Crucially, we demonstrated that
pharmacological inhibition of USP13 sensitises HPV posi-
tive cervical cancer cells to BH3 mimetic inhibitors, sug-
gesting that the targeting of USP13 may have therapeutic
benefit in these cancers.
Results
Increased USP13 expression in pre-malignant
cervical disease and cervical cancer
To investigate whether DUBs contribute to transformation
in cervical cancer, we analysed the cervical cancer dataset
from The Cancer Genome Atlas (TCGA) [34]. By exam-
ining the copy number alterations (CNAs) of DUB genes in
the human genome using a previously curated gene list
([35]; Supplementary Fig. 1) we observed amplification of
USP13 in approximately 15% of cervical cancers, which
was also seen in a number of other squamous carcinomas
(Supplementary Fig. 1 and Fig. 1A). Importantly, USP13
copy number positively correlated with USP13 mRNA
expression in cervical cancer (R= 0.350) (Fig. 1B). Next,
we examined the expression of USP13 in a panel of cervical
cancer cell lines. When compared to primary normal human
keratinocytes (NHKs), USP13 mRNA expression was
higher in HPV positive (HPV+ ), but not HPV negative
(HPV-) cervical cancer cells (Fig. 1C). In contrast, USP13
protein levels were increased in both HPV+ and HPV-
cervical cancer cells compared to NHKs, when analysed by
western blot (Fig. 1D). To confirm the increased USP13
protein expression in cervical cancer, we performed
immunohistochemistry (IHC) on a cervical cancer tissue
microarray (TMA). In line with the data from cell lines,
USP13 protein expression was significantly higher in the
cervical cancer tissue (Fig. 1E). The development of cer-
vical cancer occurs over many years, through the accumu-
lation of pre-malignant alteration of the squamous epithelia
collectively known as cervical intraepithelial neoplasia
(CIN); CIN1 represents a transient HPV infection with mild
dysplasia, while CIN3 represents severe dysplasia which
may develop into cervical cancer [36]. To investigate if
USP13 expression may contribute to the development of
cervical cancer, we analysed USP13 mRNA expression in
cervical cytology samples from a cohort of HPV16+
patients. Samples from healthy, HPV- patients were used as
controls. USP13 mRNA expression and the levels of USP13
protein both increased during progression through CIN1 to
CIN3 (Fig. 1F, G). In validation of our data in cervical
cancer cell lines and cervical cancer tissue, USP13 mRNA
expression was also significantly upregulated in several
published microarray databases (Supplementary Fig. 2),
suggesting that increased USP13 expression is a common
occurrence in cervical cancer.
HR-HPV oncogenes do not modulate USP13
expression in cervical cancer
Our cell line data showed higher USP13 expression in HPV
+ cervical cancer cells compared to normal control cells
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(Fig. 1C, D). To investigate if the HPV oncogenes could
directly induce USP13 expression, we first transiently
expressed HR-HPV E6 and E7, alone or in combination, in
HPV- C33A cells. When expressed alone, neither oncogene
increased USP13 expression; co-expression of both E6 and
E7 led to a small, but non-significant, increase in USP13
expression. Western blot was used to confirm appropriate
expression of each oncoprotein. We did note a lower
expression of E6 in the co-expression samples, although it
was still detectable using antibodies against E6 and GFP
(Supplementary Fig. 3A, B). Furthermore, depletion of
endogenous E6/ E7 in HeLa cells did not alter USP13
expression (Supplementary Fig. 3C, D). To confirm our
experimental studies, we analysed USP13 expression in the
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TCGA cervical cancer dataset based on HPV status (Sup-
plementary Fig. 3E). In agreement with our cell line data,
USP13 expression was not significantly different between
HPV+ and HPV- cervical cancer. These data together
suggest that HPV does not directly modulate USP13
expression in cervical cancer.
USP13 expression is regulated by c-Jun/AP-1 in
cervical cancer cells
In addition to the USP13 amplification observed by our
analysis of the TCGA cervical cancer dataset (Fig. 1A), we
noted that several cases had high USP13 mRNA expression
in the absence of USP13 amplification. We therefore wished
to further investigate how USP13 expression is regulated in
cervical cancer. Whilst oncogenes can be upregulated in
cancer at the transcriptional level, the transcriptional reg-
ulation of USP13 is poorly understood. To gain insight, we
analysed the putative USP13 promoter region upstream of
the USP13 start codon for transcription factor binding sites
(Fig. 2A). We identified two AP-1 like sequences that have
previously been shown to bind to c-Jun, a member of the
AP-1 transcription factor family that is highly active in
cervical cancer [37, 38]. To test if c-Jun/AP-1 regulates
USP13 expression we first inhibited the activity of the MAP
kinase (MAPK) JNK, which is an important inducer of
c-Jun/AP-1 signalling [39]. Addition of the potent, specific
irreversible JNK inhibitor JNK-IN-8 abrogated c-Jun
phosphorylation and reduced c-Jun expression, as pre-
viously observed. Furthermore, we saw a substantial
reduction in USP13 protein expression (Fig. 2B). JNK
inhibition also decreased USP13 mRNA expression,
demonstrating that JNK-mediated c-Jun activity may reg-
ulate USP13 at the transcriptional level (Fig. 2C). To
investigate if c-Jun directly played a role, we depleted c-Jun
expression using a pool of specific siRNAs. Knockdown of
c-Jun resulted in a significant decrease in USP13 mRNA
and protein expression in both HeLa and SiHa cells
(Fig. 2D, E). Finally, we assessed if c-Jun regulated USP13
expression directly, by binding the USP13 promoter via the
putative AP-1 binding sites. We performed chromatin
immunoprecipitation (ChIP) analysis utilising primers cov-
ering the AP-1 like sequences in the USP13 promoter
(termed AP-1-1 and AP-1–2; Fig. 2A). In DMSO treated
HeLa cells, there was a significant enrichment of c-Jun
binding to the AP-1-1 site in the USP13 promoter compared
to an IgG isotype control. In contrast, little to no binding of
c-Jun was observed at AP-1–2 (Fig. 2F). Crucially, c-Jun
binding to the AP-1-1 site was dependent on JNK activity,
as treatment with JNK-IN-8 abolished c-Jun binding to the
USP13 promoter. Taken together, JNK-dependent c-Jun
activation is necessary for USP13 expression in cervical
cancer cells.
USP13 is required for HPV+ cervical cancer cell
proliferation
Depletion of USP13 using a pool of specific siRNAs
(Fig. 3A) caused a significant reduction in HPV+ cervical
cancer cell growth (Fig. 3B). The absence of USP13 also led
to a reduction in colony formation under anchorage dependent
(Fig. 3C) and independent conditions (Fig. 3D). In contrast,
depletion of USP13 had minimal impact on cell proliferation
or colony formation in HPV- cervical cancer cells (Supple-
mentary Fig. 4A–C). Conversely, over-expression of wild
type (WT) USP13 enhanced cell growth and colony forma-
tion in HPV+ cell lines (Fig. 3E–H). This enhancement was
dependent on USP13 deubiquitinase activity, as a catalytically
inactive mutant of USP13 (USP13 C345A) failed to increase
cell growth. Together, these results show that expression of
catalytically active USP13 is required for the proliferation of
HPV+ cervical cancer cells.
USP13 promotes Mcl-1 stability
Several USP13 targets have been identified, including
microphthalmia-associated transcription factor (MITF),
ATP citrate lyase (ACLY) and phosphatase and tensin
homolog (PTEN) [40–42]. Interestingly, USP13 was
Fig. 1 USP13 expression is upregulated in pre-malignant cervical
disease and cervical cancer. A Genomic alterations of USP13 across
human cancers determined by cBioportal analysis of TCGA data. B
Scatter dot plot analysis of USP13 mRNA expression against USP13
copy number alterations in cervical cancer determined by cBioportal
analysis of TCGA data. Correlation was determined using Spearman’s
analysis. C RT-qPCR analysis of USP13 mRNA expression in normal
human keratinocytes (NHKs), HPV- C33A cells, HPV16+ SiHa and
CaSKi cells and HPV18+ SW756 and HeLa cells. mRNA expression
was normalized against U6 mRNA levels. D Representative western
blot of USP13 expression in NHKs, C33A cells, SiHa, CaSKi, SW756
and HeLa cells. GAPDH served as a loading control. Quantification of
the protein band intensities from four biological, independent repeats
are shown on the right. E Representative immunohistochemical (IHC)
staining of USP13 expression in cervical cancer tissues and normal
cervical epithelium from a tissue microarray (TMA). Scale bars,
100 μm. Scatter dot plot analysis of USP13 expression from a larger
cohort of cervical cancer cases (n= 41) and normal cervical epithe-
lium (n= 9) is shown on the right. F Scatter dot plot of RT-qPCR
analysis of USP13 mRNA expression from a panel of cervical cytol-
ogy samples representing CIN lesions of increasing grade. Five sam-
ples from each clinical grade (negative (Neg) and CIN I-III) were
analysed and mRNA levels were normalized to the negative samples.
Samples were normalized against U6 mRNA levels. G Representative
western blot of cervical cytology samples of CIN lesions of increasing
grade analysed for USP13 protein expression. GAPDH served as a
loading control. Scatter dot plot analysis of a larger cohort of samples
(n= 15 for each grade) is shown on the right. Bars represent the mean
± standard deviation from at least three biological repeats unless
otherwise stated. *p < 0.05; **p < 0.01; ***p < 0.001 (Student’s t-test).
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recently shown to deubiquitinate and stabilise the pro-
survival protein Mcl-1 in lung and ovarian cancers [43].
Like cervical cancer, ovarian cancers are squamous cell
carcinomas; therefore, we hypothesised that USP13 might
also regulate Mcl-1 in cervical cancer cells. To investigate
this, the level of Mcl-1 expression was analysed in USP13
depleted cells. Loss of USP13 significantly reduced Mcl-1
protein expression, without effecting MCL1 mRNA
expression (Fig. 4A, B). Critically, treatment of USP13
depleted cells with the proteasome inhibitor MG132 rescued
Mcl-1 protein levels, suggesting that USP13 protects Mcl-1
from proteasomal degradation (Fig. 4C). As a com-
plementary approach, the over-expression of USP13 caused
an increase in Mcl-1 protein levels (Fig. 4D). This was
dependant on the catalytic activity of USP13, as a cataly-
tically inactive USP13 mutant did not increase Mcl-1 pro-
tein levels (Fig. 4D). Again, USP13 over-expression had no
effect on MCL1 mRNA expression (Fig. 4E), suggesting
that the regulation of Mcl-1 by USP13 is post transcrip-
tional. Interestingly, over-expression or depletion of USP13
did not modulate Mcl-1 expression in HPV- C33A cells
(Supplementary Fig. 5A, B), suggesting that Mcl-1
expression is not regulated by USP13 in these cells. The
effect of USP13 on Mcl-1 protein turnover was investigated
by cycloheximide chase assay. When USP13 was depleted
from HeLa cells, the half-life of Mcl-1 was markedly
Fig. 2 USP13 expression is regulated by c-Jun/AP-1 activity in
cervical cancer cells. A Schematic of potential AP-1 binding sites in
the USP13 promoter region. B Representative western blot of HeLa
and SiHa cells after treatment with JNK-IN-8 (3 µM) or DMSO control
for 48 h. Lysates were analysed for the expression of USP13, phos-
phorylated c-Jun (S73) and c-Jun. GAPDH was used as a loading
control. C RT-qPCR analysis of USP13 mRNA expression in HeLa
and SiHa cells after treatment with JNK-IN-8 (3 µM) or DMSO control
for 48 h. mRNA expression was normalized against U6 mRNA levels.
D Representative western blot of HeLa and SiHa cells after transfec-
tion of a pool of four specific c-Jun siRNA for 72 h. Lysates were
analysed for the expression of USP13 and c-Jun. GAPDH was used as
a loading control. E RT-qPCR analysis of USP13 and cJUN mRNA
expression of HeLa and SiHa after transfection of a pool of four
specific c-Jun siRNA for 72 h. mRNA expression was normalized
against U6 mRNA levels. F Cells were treated as in B and chromatin
was prepared from HeLa cells and c-Jun was immunoprecipitated
using an anti-c-Jun antibody, followed by RT-qPCR using primers
specific to the two putative AP-1 binding sites in the USP13 promoter.
c-Jun binding is presented as percentage of input chromatin. Bars are
the means ± standard deviation from at least three biological repeats.
*p < 0.05; **p < 0.01; ***p < 0.001 (Student’s t-test).
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reduced, from ~65 min to ~20 min (Fig. 4F). Conversely,
overexpression of WT USP13, but not the USP13 mutant,
enhanced the half-life of Mcl-1 to ~300 min (Fig. 4G).
These data demonstrate that USP13 promotes the stability
of Mcl-1 in HPV+ cervical cancer cells by protecting it
from proteasomal degradation.
Fig. 3 USP13 expression is required for the proliferation of HPV
+ cervical cancer cells. A Representative western blot of HeLa and
SiHa cells after transfection of a pool of four specific USP13 siRNA
for 72 h. Lysates were analysed for the expression of USP13 and
GAPDH was used as a loading control. B Growth curve analysis of
HeLa and SiHa cells after transfection of a pool of four specific
USP13 siRNA for 72 h. C Colony formation assay (anchorage
dependent growth) of HeLa and SiHa cells after transfection of a pool
of four specific USP13 siRNA for 72 h. D Soft agar assay of HeLa and
SiHa cells after transfection of a pool of four specific USP13 siRNA
for 72 h. E Representative western blot of HeLa and SiHa cells after
transfection of a FLAG-USP13 or FLAG-USP13 (C345A) for 48 h.
Lysates were analysed for the expression of USP13 and GAPDH was
used as a loading control. F Growth curve analysis of HeLa and SiHa
cells after transfection of a FLAG-USP13 or FLAG-USP13 (C345A)
for 48 h. G Colony formation assay (anchorage dependent growth) of
HeLa and SiHa cells after transfection of a FLAG-USP13 or FLAG-
USP13 (C345A) for 48 h. H Soft agar assay of HeLa and SiHa cells
after transfection of a FLAG-USP13 or FLAG-USP13 (C345A) for
48 h. Bars are the means ± standard deviation from at least three
biological repeats. *p < 0.05; **p < 0.01; ***p < 0.001 (Student’s
t-test).
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Fig. 4 USP13 promotes the stability of the pro-survival protein
Mcl-1. A Representative western blot of HeLa and SiHa cells after
transfection of a pool of four specific USP13 siRNA for 72 h. Lysates
were analysed for the expression of USP13 and Mcl-1. GAPDH was
used as a loading control. B RT-qPCR analysis of USP13 and MCL1
mRNA expression of HeLa and SiHa cells after transfection of a pool
of four specific USP13 siRNA for 72 h. mRNA expression was nor-
malized against U6 mRNA levels. C Representative western blot of
HeLa and SiHa cells after transfection of a pool of four specific
USP13 siRNA for 72 h. Cells were additionally treated with 10 µM
MG132 for 6 h. Lysates were analysed for the expression of USP13
and Mcl-1. GAPDH was used as a loading control. D Representative
western blot of HeLa and SiHa cells after transfection of FLAG-
USP13 or FLAG-USP13 (C345A). Lysates were analysed for the
expression of USP13 and Mcl-1. GAPDH was used as a loading
control. E RT-qPCR analysis of USP13 and MCL1 mRNA expression
of HeLa and SiHa cells after transfection of FLAG-USP13 or FLAG-
USP13 (C345A). mRNA expression was normalized against U6
mRNA levels. F Representative western blot of HeLa cells after
transfection of a pool of four specific USP13 siRNA for 72 h. Cells
were additionally treated with 20 µM cycloheximide and harvested at
the indicated time points. Lysates were analysed for the expression of
USP13 and Mcl-1. GAPDH was used as a loading control. Quantifi-
cation of the protein band intensities from three biological, indepen-
dent repeats are shown on the right. G Representative western blot of
HeLa cells after transfection of FLAG-USP13 or FLAG-USP13
(C345A). Cells were additionally treated with 20 µM cycloheximide
and harvested at the indicated time points. Lysates were analysed for
the expression of USP13 and Mcl-1. GAPDH was used as a loading
control. Quantification of the protein band intensities from three bio-
logical, independent repeats are shown on the right. Bars are the means
± standard deviation from at least three biological repeats. *p < 0.05;
**p < 0.01; ***p < 0.001 (Student’s t-test).
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USP13 interacts with and deubiquitinates Mcl-1 in
cervical cancer cells
USP13 has previously been shown to directly bind to Mcl-
1 in vitro [43]. Furthermore, Mcl-1 has also been shown to
be highly expressed in cervical cancer and correlates with
proliferation and cell survival [44]. We first performed co-
immunoprecipitation assays to confirm the interaction
between USP13 and Mcl-1 by transfecting HEK293T cells
with FLAG-USP13 and V5-hMcl-1. Immunoprecipitation
with anti-FLAG antibody demonstrated that FLAG-
USP13 interacted with over-expressed Mcl-1 (Fig. 5A).
Furthermore, reciprocal immunoprecipitations using anti-
V5 antibody confirmed this interaction (Fig. 5A). To
identify if this interaction also occurred between endo-
genous USP13 and Mcl-1 in cervical cancer cells,
immunoprecipitations were performed with either anti-
USP13 or anti-Mcl-1 antibodies in HeLa and SiHa cells
lysates. Immunoprecipitation with either antibody resulted
in the detection of both USP13 and Mcl-1, suggesting that
the endogenous proteins interact in cervical cancer cells
(Fig. 5B). Next, we confirmed that USP13 deubiquitinated
Mcl-1. HEK293T cells were transfected with FLAG-
USP13, V5-Mcl-1 and HA-Ubiquitin, and anti-V5
immunoprecipitates were probed for the level of ubiqui-
tination using the HA-antibody. Co-expression of USP13
and Mcl-1 led to a marked reduction in Mcl-1 ubiquiti-
nation (Fig. 5C, compare lanes 2 and 3). Consistent with
our previous data, the catalytically inactive USP13 mutant
was not able to reduce Mcl-1 ubiquitination, despite
retaining the ability to bind to Mcl-1 (Fig. 5C, compare
lanes 2 and 4; Supplementary Fig. 6). Whilst in vitro
ubiquitination assays confirmed that USP13 is capable of
directly deubiquitinating Mcl-1 [43], the precise ubiquitin
linkage that USP13 removes from Mcl-1 has not been
determined. Ubiquitin contains seven lysine residues that
serve as sites of ubiquitination. The most studied types are
K48 polyubiquitin, which targets proteins for degradation,
and K63 polyubiquitin, which is predominantly associated
with signal transduction [3]. To determine which ubiquitin
linkage USP13 deubiquitinates, HEK293T cells were
transfected with the HA-tagged K48R or K63R ubiquitin
mutants, which are unable to be polyubiquitinated with
K48 or K63 linkages, respectively. Overexpressed USP13
was able to cleave wild-type and the K63R form of ubi-
quitin from Mcl-1 but not K48R ubiquitin (Fig. 5D).
These results suggest that USP13 removes K48 poly-
ubiquitin, but not K63 polyubiquitin, chains from Mcl-1.
Finally, we confirmed that depletion of USP13 from both
HeLa and SiHa cells increased the ubiquitination of
endogenous Mcl-1, suggesting USP13-mediated deubi-
quitination of Mcl-1 is relevant in cervical cancer cells
(Fig. 5E).
Restoration of Mcl-1 expression partially rescues the
proliferation defect in USP13 depleted cervical
cancer cells
As well as having a critical role in cell survival, Mcl-1 can
also play an important role in cell proliferation [45]. As
USP13 depletion resulted in the inhibition of cell proliferation
in cervical cancer cells, we investigated if this was due to the
reduction in Mcl-1 levels. We therefore over-expressed Mcl-1
alone or in in USP13-depleted cells (Fig. 6A). Expression of
Mcl-1 alone led to a modest increase in cell proliferation and
colony formation (Fig. 6B). Importantly, the re-introduction
of Mcl-1 in USP13-depleted cells resulted in a partial
restoration of proliferation (Fig. 6B) and colony formation
(Fig. 6C). These results suggest that the effect of USP13 on
cell proliferation in cervical cancer cells is at least partially
dependent on the stabilisation of Mcl-1 expression.
USP13 and Mcl-1 expression correlate in cervical
cancer
To confirm the clinical relevance of the USP13 – Mcl-1
interaction, we first analysed the expression of Mcl-1 in our
panel of cervical cancer cells. Mcl-1 protein levels were
significantly higher in cervical cancer cells when compared
to NHKs (Fig. 7A) and correlated with increased USP13
expression in the cervical cancer cell lines (R= 0.862,
p= 0.015). We assessed Mcl-1 expression in cervical can-
cer tissue by immunohistochemistry and observed higher
expression of Mcl-1 in cervical cancer tissue when com-
pared to non-cancer tissue (Fig. 7B, C). Importantly,
expression of Mcl-1 significantly correlated with USP13
expression in cervical cancer tissue from the same patient
(Fig. 7D; R= 0.4128, p= 0.009). Collectively, these find-
ings demonstrate that USP13 and Mcl-1 are concomitantly
over expressed in cervical cancer tissue, suggesting that the
regulation of Mcl-1 by USP13 is clinically relevant.
Inhibition of USP13 sensitises cervical cancer cells to
BH3 mimetics
BCL-2 family members are highly expressed in cervical
cancer and inhibition of these proteins using BH3 mimetics
is a promising therapeutic strategy [46]. Despite this pro-
mise, high expression levels of Mcl-1 is commonly asso-
ciated with resistance to these inhibitors and inhibition or
depletion of Mcl-1 can restore sensitivity to BH3 mimetics
[47]. To investigate if targeting USP13 to reduce Mcl-1
expression has therapeutic potential in cervical cancer, we
first assessed the impact of USP13 inhibition by the small
molecule inhibitor Spautin-1 [48]. In both HeLa and SiHa
cells, inhibition of USP13 by Spautin-1 resulted in a dose-
dependent decrease in Mcl-1 protein expression (Fig. 8A).
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Fig. 5 USP13 interacts with and deubiquitinates Mcl-1 in cervical
cancer cells. A HEK293T cells were transfected with V5-Mcl-1, Flag-
USP13, or both V5-Mcl-1 and FLAG-USP13. Cells were treated with
10 µM MG132 for 6 h and either Mcl-1 or USP13 were immunopre-
cipitated using an anti-V5 or anti-FLAG antibody. Co-
immunoprecipitated Mcl-1 or FLAG-USP13 were detected using the
respective antibodies. GAPDH was used as a loading control.
B Endogenous Mcl-1 and USP13 were immunoprecipitated from
HeLa and SiHa cells after treatment with 10 µM MG132 using an anti-
Mcl-1 or anti-USP13 antibodies. Co-immunoprecipitated Mcl-1 or
USP13 were detected using the respective antibodies. GAPDH was
used as a loading control. C HEK293T cells were co-transfected with
V5-Mcl-1 and HA-Ubiquitin, with or without Flag-USP13 or a FLAG-
USP13 mutant (C345A). Cells were treated with 10 µMMG132 for 6 h
and V5-Mcl-1 was immunoprecipitated using an anti-Mcl-1 antibody.
Ubiquitinated Mcl-1 was detected using an anti-HA antibody.
D HEK293T cells were co-transfected with V5-Mcl-1, HA-Ubiquitin
or mutant Ubiquitin (K48R or K63R), with or without Flag-USP13.
Cells were treated with 10 µM MG132 for 6 h and V5-Mcl-1 was
immunoprecipitated using an anti-V5 antibody. Ubiquitinated Mcl-1
was detected using an anti-HA antibody. E HeLa and SiHa cells were
transfected with a pool of four specific USP13 siRNA for 72 h. Cells
were treated with 10 µM MG132 for 6 h before harvesting. Mcl-1 was
immunoprecipitated using an anti-Mcl-1 antibody. Ubiquitinated Mcl-
1 was detected using an anti-ubiquitin antibody. GAPDH was used as
a loading control.
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Spautin-1 also reduced USP13 expression, as has been
previously observed in other cell lines (Fig. 8A). Similar to
USP13 depletion, treatment with Spautin-1 had no effect on
MCL1 mRNA expression (Fig. 8B). Furthermore, the
reduction in Mcl-1 protein expression upon Spautin-1
treatment was lessened by inhibition of the proteasome
(Fig. 8C). Treatment with Spautin-1 also abolished the
increase in Mcl-1 expression observed upon USP13 over-
expression, suggesting that the function of Spautin-1 may
be through the inhibition of USP13 (Fig. 8D). Cervical
cancer cells are inherently resistant to the BH3 mimetic
ABT-263 [49]. We therefore investigated if pharmacologi-
cal inhibition of USP13 using Spautin-1 sensitised cervical
cancer cells to ABT-263. In line with previous reports,
HeLa and SiHa cells were relatively insensitive to ABT-
263, with an IC50 of 10.64 and 18.58 μM, respectively
(Fig. 8E). However, combination treatment with Spautin-1
significantly sensitised cervical cancer cells to ABT-263
(HeLa, 12-fold increase, 10.64 μM to 0.89 μM; SiHa, 15-
fold increase, 18.58 μM to 1.32 μM). Furthermore, in line
with our proliferation data, Spautin-1 did not significantly
alter the response of HPV- C33A cells to ABT-263
treatment (Supplemantary Fig. 7; ABT-263 IC50 11.56 μM
vs 10.25 μM with Spautin-1 co-treatment). To expand on
this, we performed dose matrix experiments containing a
range of ABT-263 and Spautin-1 concentrations and
assessed potential drug synergy using the Bliss indepen-
dence model [50]. An overall negative Bliss synergy score
indicates antagonism; a value of zero indicates additive
activity, and positive Bliss synergy score indicates synergy.
The heatmaps for Bliss synergy scores showed that ABT-
263 in combination with Spautin-1 synergistically inhibited
cell viability across multiple concentrations (Fig. 8F).
As a single agent, ABT-263 did not induce apoptosis in
cervical cancer cells, whereas Spautin-1 alone did, particu-
larly in SiHa cells (Fig. 8G). Combination treatment resulted
in around a 15-fold increase in apoptosis in both cell lines
(Fig. 8G). Finally, we demonstrated that whilst Spautin-1
reduced colony formation by around 50% (similar to USP13
depletion), combination treatment with ABT-263 resulted in
a 75% reduction in colony formation (Fig. 8H). Taken
together, these data suggest that USP13 mediated stabilisa-
tion of Mcl-1 may be a potential mechanism for the resis-
tance of cervical cancer cells to BH3 mimetics.
Fig. 6 Restoration of Mcl-1 expression partially rescues the pro-
liferation defect in USP13 depleted cervical cancer cells. A
Representative western blot of HeLa and SiHa cells after transfection
of a pool of four specific USP13 siRNA, or scramble siRNA, for 72 h.
After 24 h, cells were transfected with hMcl-1 or control vector.
Lysates were analysed for the expression of USP13, Mcl-1 and
GAPDH was used as a loading control. B Growth curve analysis of
HeLa and SiHa cells after transfection of a pool of four specific
USP13 siRNA, or scramble siRNA, for 72 h. After 24 h, cells were
transfected with hMcl-1 or control vector. C Colony formation assay
(anchorage dependent growth) of HeLa and SiHa cells after transfec-
tion of a pool of four specific USP13 siRNA, or scramble siRNA, for
72 h. After 24 h, cells were transfected with hMcl-1 or control vector.
Bars are the means ± standard deviation from at least three biological
repeats. *p < 0.05; **p < 0.01; ***p < 0.001 (Student’s t-test).
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Discussion
Deregulation of the ubiquitin system is a common occur-
rence in diverse cancers [51]. As such, targeting the
enzymes responsible for either the addition or removal of
ubiquitin offers a potential therapeutic avenue. Encoura-
gingly, a number of small molecule inhibitors of ubiquitin-
associated enzymes are currently entering pre-clinical trials
[52–56]. Here, we screened the TCGA cervical cancer
database for the expression of DUBs, enzymes which cat-
alyse the remove of ubiquitin from protein substrates [5].
We identified that USP13 is the most amplified DUB gene
in cervical cancer. Interestingly, USP13 sits on chromosome
3q26.33, in the so-called 3q26 ‘OncCassette’, a common
amplicon that is found in most squamous cell carcinomas
and includes the oncogene PIK3CA [57]. In addition, the
TCGA cervical cancer database shows minimal mutations
in the USP13 gene (data not shown).
Several substrates for USP13 have recently been identi-
fied; however, due to this, the function of USP13 in
tumourigenesis is controversial, as it has been shown to
regulate the expression of both tumour suppressors and
oncogenes. USP13 can induce Beclin-1 mediated autop-
hagy as part of a p53 regulatory loop [48] and stabilise the
tumour suppressor PTEN in breast cancer [41]. In contrast,
USP13 also deubiquitinates and stabilises microphthalmia-
associated transcription factor (MITF), an important
lineage-specific master regulator in melanoma [40, 58].
Furthermore, USP13 can deubiquitinate and stabilise
ACLY/OGDH and c-Myc in ovarian cancer and glio-
blastoma, respectively, thereby functioning as an oncogene
[42, 59]. Indeed, USP13 depletion did induce a proliferation
defect in some ovarian cancer cells but not others, and this
was dependent on USP13 expression levels [42, 43].
Interestingly, despite the fact that the viral oncogenes do not
regulate USP13 expression, depletion of USP13 in HPV-
C33A cells did not cause a proliferation defect (Supple-
mentary Fig. 4). This may be due to the fact that USP13 did
not seem to regulate Mcl-1 in these cells (Supplementary
Fig. 5). The reason for the this is unclear at this point;
further studies are required in a larger panel of HPV- cer-
vical cancer cells to ascertain a mechanism for the effects
Fig. 7 USP13 and Mcl-1 expression correlate in cervical cancer.
A Representative western blot of Mcl-1 expression in normal human
keratinocytes (NHKs), C33A, SiHa, CaSKi, SW756 and HeLa cells.
GAPDH served as a loading control. B Representative IHC staining of
Mcl-1 expression in cervical cancer tissues and normal cervical epi-
thelium from a tissue microarray (TMA). Scale bars, 100 μm. C Scatter
dot plot analysis of Mcl-1 expression from a larger cohort of cervical
cancer cases (n= 41) and normal cervical epithelium (n= 9) is shown
on the right. D Representative IHC staining of USP13 and Mcl-1
expression in cervical cancer tissue from two patients. Staining was
performed from separate cores from the same patient samples. Scale
bars, 100 μm. Correlation was determined using Spearman’s analysis
and is shown on the right. *p < 0.05; **p < 0.01; ***p < 0.001 (Stu-
dent’s t-test).
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observed in this study. As well as being regulated via copy
number alterations, genes can also be regulated at a tran-
scriptional level. The cervical cancer TCGA dataset
demonstrates that 8% of cervical cancers have high USP13
mRNA expression in the absence of USP13 copy number
amplification. We therefore investigated how USP13
expression was regulated in cervical cancer cells. We
identified that the USP13 promoter contains two AP-1-like
sequences that have previously been shown to bind to the
AP-1 family member c-Jun [37, 38]. In this study, we
demonstrated that inhibition of JNK, or depletion of c-Jun,
resulted in a substantial loss of USP13 expression and
this was regulated at the transcriptional level (Fig. 2B–E).
Furthermore, chromatin immunoprecipitation assays
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demonstrated that c-Jun directly bound one of the identified
AP-1-like sequences in the USP13 promoter (Fig. 2A, F).
Thus, we have identified an additional mechanism of
USP13 regulation. The BCL-2 family is composed of pro-
apoptotic and anti-apoptotic proteins that play a critical role
in regulating cell survival. Mcl-1, along with other proteins
such as BCL-2 and BCL-XL, are anti-apoptotic members of
the BCL-2 family and have been shown to promote cell
survival, chemotherapeutic resistance and are frequently
dysregulated in a variety of human cancers (reviewed in
[60]). Thus, the regulation of these proteins may be a
potential therapeutic target in several cancers. Here, we
provide evidence that USP13 functions as an oncogene in
cervical cancer by promoting cell proliferation and further
demonstrate that this is linked with the stabilisation of the
pro-survival BCL-2 family member Mcl-1, by specifically
removing K48 polyubiquitin chains that are associated with
proteasomal degradation.
In lung and ovarian cancers, where USP13 also regulates
Mcl-1 stability, USP13 does not contribute to the cell pro-
liferation of unstressed cells (Fig. 3). Interestingly,
restoration of Mcl-1 expression only partially restored cell
proliferation in USP13 depleted cervical cancer cells. This
suggests that additional USP13 substrates may contribute to
cervical cancer cell proliferation. Further studies will be
required to identify these targets and understand how they
contribute to USP13-mediated cell proliferation. Over
recent years, Mcl-1 has attracted attention as a potential
therapeutic target in cancer [61, 62]. Mcl-1 plays a critical
role as a pro-survival factor, as well as a pro-proliferative
factor, in many tumour types. Furthermore, Mcl-1 turnover
can be controlled by a number of E3 ligases (such as
SCFβ-TrCP, SCFFBW7 and Mule) and DUBs (such as USP9X
and DUB3) (reviewed in [63]). Previously, the DUBs
OTUD1 and JOSD1 had been shown to regulate Mcl-1
expression in cervical cancer cells [64, 65]. In contrast to
the data presented here, one of these studies did not find a
role for USP13 in the regulation of Mcl-1 in HeLa cells
[64]; however, that study focussed on the overexpression of
USP13. In contrast, we have taken a more holistic approach
and assessed the role of USP13 in Mcl-1 stabilisation with a
range of complementary assays, providing robust evidence
that USP13 can indeed regulate Mcl-1 expression in cer-
vical cancer cells. Furthermore, whilst our data demon-
strates that USP13 plays a role in regulating cervical cancer
cell proliferation via the stabilisation of Mcl-1, it is clear
that several other DUBs play complimentary roles in reg-
ulating Mcl-1 expression that may also play pro-oncogenic
roles in cervical cancer. As BCL-2 family members have
been reported to be highly expressed in cervical cancer,
BH3 mimetics may have therapeutic potential in these
cancers and the high expression of Mcl-1 has been impli-
cated as a resistance mechanism to these inhibitors [46, 47].
Recent advances have resulted in the development of ABT-
737, a potent BH3 mimetic which disrupts the interaction
between anti-apoptotic and pro-apoptotic BCL-2 proteins
[66]. In addition, the orally bioavailable analogue ABT-263
(navitoclax) was evaluated in clinical trials and resulted in
significant anti-tumour activity [67]. Subsequently, ABT-
199 (venetoclax) was developed, a highly selective BCL-2
inhibitor that has been approved for patients with chronic
lymphocytic leukemia (CLL) harbouring 17p deletion who
have received at least one prior treatment [68]. Despite their
promise, an inherent problem with the current BH3
mimetics, is the development of intrinsic resistance due to
high expression of Mcl-1, which these inhibitors do not
target [69, 70]. Therefore, reducing Mcl-1 expression, by
direct or indirect inhibition, can sensitise resistant cancer
cells to BH3 mimetics [70, 71]. As such, Mcl-1 specific
inhibitors, such as AMG 176, can synergise with BH3
mimetics to achieve tumour regression in acute myeloid
leukemia (AML) tumour models [69]. Furthermore, studies
with cyclin-dependent kinase (CDKs) inhibitors such as
alvocidib, or multi-kinase inhibitors such as Sorafenib have
shown similar results [72, 73].
Our data shows that USP13 and Mcl-1 protein expression
correlates, suggesting that USP13-mediated Mcl-1 stabilisa-
tion is clinically relevant. Furthermore, we demonstrated that
this mechanism could be exploited pharmacologically, by
use of a recently identified small molecule inhibitor of
USP13 to reduce Mcl-1 protein expression [48]. This may
have potential benefit in cervical cancer patients, as although
standard chemotherapeutic options in cervical cancer have
good efficacy, many cases develop local recurrences and
metastases [74]. Our data demonstrate that inhibition of
Fig. 8 Pharmacological inhibition of USP13 sensitises HPV+
cervical cancer cells to BH3 mimetics. A Representative western blot
of HeLa and SiHa cells after treatment with increasing doses of
Spautin-1 or DMSO control for 48 h. Lysates were analysed for the
expression of USP13 and Mcl-1. GAPDH was used as a loading
control. B RT-qPCR analysis ofMCL1 mRNA expression in HeLa and
SiHa cells after treatment with Spautin-1 (10 µM) or DMSO control
for 48 h. mRNA expression was normalized against U6 mRNA levels.
C HeLa and SiHa cells were treated with Spautin-1 (10 µM) or DMSO
control for 48 h. Cells were additionally treated with 10 µM MG132
for 6 h. Lysates were analysed for the expression of USP13 and Mcl-1.
GAPDH was used as a loading control. D Representative western blot
of HeLa and SiHa cells after transfection of FLAG-USP13 with or
without Spautin-1 (10 µM) or DMSO control. Lysates were analysed
for the expression of USP13 and Mcl-1. GAPDH was used as a
loading control. E Cell viability assay (MTT) of HeLa and SiHa cells
treated with increasing doses of ABT-263, with or without Spautin-1
(10 μM), for 24 h. F Synergistic activities of Spautin-1 and ABT-263
in HeLa and SiHa cells. Left: heatmaps of growth inhibition; right:
Bliss synergy map. G Flow cytometric analysis of Annexin V assay in
HeLa and SiHa cells after treatment with DMSO, Spautin-1 (10 μM),
ABT-263 (5 μM) or both for 24 h. H Colony formation assay of HeLa
and SiHa cells after treatment with DMSO, Spautin-1 (10 μM), ABT-
263 (5 μM) or both for 24 h. Error bars represent the mean ± standard
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USP13 with Spautin-1 reduces Mcl-1 expression and sen-
sitises cervical cancer cells to the BH3 mimetic ABT-263,
offering a potential therapeutic strategy for cervical cancer.
In conclusion, we have identified that the DUB USP13 is a
potential oncogene in cervical cancer that promotes pro-
liferation by deubiquitinating and stabilising the pro-survival
protein Mcl-1. We also demonstrate that pharmacological
inhibition of USP13 sensitises cervical cancer cells to a BH3
mimetic inhibitor by reducing Mcl-1 protein expression,
inducing cell death. Therefore, we suggest that targeting
USP13 may offer a therapeutic benefit in cervical cancer
patients via the reduction in Mcl-1 protein expression.
Materials and methods
Cervical cytology samples
Cervical cytology samples were obtained from the Scottish
HPV Archive (http://www.shine/mvm.ed.ac.uk/archive.shtml),
a biobank of over 20,000 samples designed to facilitate HPV
research. The East of Scotland Research Ethics Service has
given generic approval to the Scottish HPV Archive as a
Research Tissue Bank (REC Ref 11/AL/0174) for HPV rela-
ted research on archive samples. Samples are available for the
present project though application to the Archive Steering
Committee (HPV Archive Application Ref 0034). RNA and
protein were extracted from the samples using Trizol as
described by the manufacturer (ThermoFischer Scientific,
USA) and analysed as described.
Tissue microarray and immunohistochemistry
A cervical cancer tissue microarray (TMA) containing 39
cases of cervical cancer and 9 cases of normal cervical
tissue (in duplicate) were purchased from GeneTex, Inc.
(GTX21468). Slides were deparaffinised in xylene, rehy-
drated in a graded series of ethanol solutions and subjected
to antigen retrieval in citric acid. Slides were blocked in
normal serum and incubated in primary antibody (USP13
(D4P3M; 12577, Cell signalling Technologies (CST)) or
Mcl-1 (S-19; sc-819, Santa Cruz Biotechnology (SCBT))
overnight at 4 °C. Slides were then processed using the
VECTASTAIN® Universal Quick HRP Kit (PK7800;
Vector Laboratories) as per the manufacturer’s instructions.
Immunostaining was visualised using 3,3’-diaminobenzi-
dine (Vector® DAB (SK-4100; Vector Laboratories)).
USP13 and Mcl-1 immunostaining quantification was
automated using ImageJ with the IHC Profiler plug-in [75].
Histology scores (H-score) were calculated based on the
percentage of positively stained tumour cells and the
staining intensity grade [76]. The staining intensities were
classified into the following four categories: 0, no staining; 1,
low positive staining; 2, positive staining; 3, strong positive
staining. H score was calculated by the following formula:
(3 x percentage of strong positive tissue) + (2 x percentage
of positive tissue) + (percentage of low positive tissue),
giving a range of 0 to 300.
Cell culture
HeLa (HPV18+ cervical adenocarcinoma cells), SW756
(HPV18+ cervical squamous carcinoma cells), SiHa
(HPV16+ cervical squamous carcinoma cells), CaSKi
(HPV16+ cervical squamous carcinoma cells) and C33A
(HPV- cervical squamous carcinoma) cells obtained from
the ATCC and grown in DMEM supplemented with 10%
FBS (ThermoFisher Scientific, USA) and 50 U/mL peni-
cillin. Primary normal human keratinocytes (NHKs) were
maintained as in [77]. Cells were negative for Mycoplasma
during this investigation. Cell identify was confirmed by
STR profiling.
Plasmids, siRNA and inhibitors
pRK5-FLAG-USP13 (Addgene plasmid #61741) and
pcDNA3.1-V5-hMcl-1 (Addgene plasmid #25375) were
purchased from Addgene (Cambridge, MA, USA). The
USP13 C345A mutant was created using the Q5 Site-
Directed Mutagenesis Kit (New England BioLabs Inc, MA,
USA) using the following primers: F – 5′ TGGGCAA
CAGCGCCTATCTCAGCTC ′3 and R – 5′ GGTTCTT
CAGACCCGTGT ′3. HA-Ubiquitin, HA-Ubiquitin (K48R)
and HA-Ubiquitin (K63R) were a kind gift from Prof. Paul
Lehner (University of Cambridge, UK). siRNA targeting
USP13 and JUN were purchased from Qiagen (FlexiTube
GeneSolution GS8975 for USP13; SI03074498,
SI03061968, 632 SI00058100, SI00058093; FlexiTube
GeneSolution GS3725 for JUN; SI03077599, SI00034678,
SI00034671, SI00034664). The small molecule inhibitors
MG132, JNK-IN-8, Spautin-1 and ABT-263 were purchased
from Calbiochem and used at the indicated concentrations.
Transfections and mammalian cell lysis
Transfection of plasmid DNA or siRNA was performed
with a DNA to Lipofectamine® 2000 (ThermoFisher) ratio
of 1:2.5. 48 or 72 h post transfection, cells were lysed in
lysis buffer for western blot analysis, or reseeded into new
plates for growth curve analysis, colony formation assays or
soft agar assays.
Deubiquitination assays
FLAG-USP13, V5-hMcl-1 and/or HA-ubiquitin plasmids
were transfected into HEK293 cells using Lipofectamine
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2000. After 40 h, the cells were treated with 20 μM MG132
(Calbiochem) for 8 h. The cells were then washed with PBS
and lysed in HEPES buffer supplemented with 100 μM N-
ethylmaleimide and protease inhibitor cocktail (Roche). The
lysates were centrifuged and incubated with 2 μg Mcl-1
antibody (S-19; sc-819, SCBT) at 4 °C overnight with
continuous rotation. A/G agarose beads were then added,
and the lysate/antibody/bead mix was incubated at 4 °C
overnight with continuous rotation. Beads were then
washed in HEPES buffer and boiled in Laemmli loading
buffer prior to SDS PAGE and western blot analysis with an
anti-HA antibody (HA-7; H9658, Sigma).
Immunoprecipitations
Assays were performed as previously described [78].
Briefly, cells were transfected with FLAG-USP13, V5-
hMcl-1 or both. Cell lysates were harvested and then
incubated with USP13, FLAG or Mcl-1 antibodies and
incubated at 4 °C overnight with continuous rotation. A/G
agarose beads were then added, and the lysate/antibody/
bead mix was incubated at 4 °C overnight with continuous
rotation. Beads were then washed in lysis buffer and boiled
in Laemmli loading buffer prior to SDS PAGE and western
blot analysis.
Western blot analysis
Equal amounts of protein from cell lysates were separated
by SDS PAGE and transferred onto a nitrocellulose mem-
brane by a semi-dry transfer method (Trans Blot® SD Semi-
Dry Transfer cell, Bio-Rad, USA). Membranes were
blocked with 5 % milk solution before incubation with
primary antibodies at 1:1000 dilution unless otherwise sta-
ted: USP13 (D4P3M; 12577, CST), Mcl-1 (S-19; sc-819,
SCBT), Phospho-c-Jun (Ser73) (D47G9; 3270, CST), c-Jun
(60A8; 9165, CST), FLAG (F1804, Sigma-Aldrich), HA
(HA-7; H9658, Sigma) and GAPDH (SCBT; sc365062)
(1:5000) as a loading control. Horseradish peroxidase
(HRP)-conjugated secondary antibodies (Sigma Aldrich,
USA) were used at a 1:5000 dilution. Proteins were detected
using WesternBright ECL (Advansta, USA) and visualised
on X-ray film.
Chromatin immunoprecipitation
Putative AP-1 binding sites in the USP13 3’UTR were
identified using the AceView program. HeLa cells were
treated with JNK-IN-8 for the required incubation time.
Cells were processed for ChIP analysis as previously
described [79]. Briefly, cells were fixed in 1% formaldehyde
for 10 min at room temperature, quenched in 0.25M glycine,
and washed in ice-cold PBS. Cells were harvested by
scraping and then lysed in cell lysis buffer (10 mM Tris-HCl,
pH 8.0, 10 mM NaCl, 0.2% NP-40, 10 mM sodium butyrate,
50 μg/ml phenylmethylsulfonyl fluoride (PMSF), 1× com-
plete protease inhibitor). Nuclei were collected by cen-
trifugation at 2,500 rpm at 4 °C and resuspended in nuclear
lysis buffer (50 mM Tris-HCl, pH 8.1, 10 mM EDTA, 1%
SDS, 10 mM sodium butyrate, 50 μg/ml PMSF, 1× complete
protease inhibitor). Extracted chromatin was then sonicated
and chromatin concentration was determined. Approxi-
mately 100 µg of chromatin from each sample was used for
the experiment. c-Jun was immunoprecipitated using a ChIP
grade anti-c-Jun antibody (60A8; 9165, CST). A/G magnetic
beads were used to pull down the antibody-chromatin
complex. To show antibody specificity, each of the samples
were pulled down with an IgG isotype control. The immu-
noprecipitated chromatin was then processed for quantitative
PCR (qPCR); the primer sequences used are available on
request. Fold-enrichment compared to negative control IgG
isotype control was calculated as in [80].
RNA extraction, cDNA synthesis and quantitative
Real Time-PCR
RNA extraction for qRT-PCR was performed using an E.Z.
N.A Total RNA Kit I (Omega bio-tek, USA). cDNA was
synthesised with 1 μg of input RNA and iScript cDNA
synthesis kit (Bio Rad, USA). qRT-PCR was performed on
the synthesised cDNA on a Corbett Rotor-Gene 6000 using
QuantiFast SYBR Green PCR kit (Qiagen, USA) and ana-
lysed using the ΔΔCT method [75] normalised to the U6
housekeeping gene. The following primer were used:
USP13 Forward 5′-GCGAAATCAGGCTATTCAGG-3′,
Reverse 5′-TTGTAAATCACCCATCTTCCTTCC-3′; MCL-
1 Forward 5′-AAAGCCTGTCTGCCAAAT-3′, Reverse 5′
CCTATAAACCCACCACTC-3′; JUN Forward 5′-TTCT
ATGACGATGCCCTCAACGC-3′, Reverse 5′-GCTCTG
TTTCAGGATCTTGGGGTTAC-3′ and U6 Forward
5′-CTCGCTTCGGCAGCACA-3′, Reverse 5′-AACGCTT
CACGAATTTGCGT-3′.
Cell viability (MTT) assays
Cells were seeded in triplicate in 96-well plates and sub-
jected to the indicated treatments for 48 h before adding
MTT reagent and measuring the absorbance at 570 nm
according to the manufacturer’s instructions (Sigma, USA).
For combination matrices, cells were seeded in 96-well
plates. After 24 h, cells were treated with ABT-263 (dose
range of 0–5 μM) and Spautin-1 (dose range of 0–20 μM) in
a 6 × 6 matrix. Cells were cultured with inhibitors for 48 h
and cell viability was determined using MTT assay as
above. The Bliss synergy heatmap and synergy score was
calculated using SynergyFinder [81].
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Colony formation assay
48 or 72 h post treatment or transfection, cells were tryp-
sinised and reseeded in a six well plate at 500 cells per well
and left to incubate for 14–21 days. Colonies were then
stained (1% crystal violet, 25% methanol) and colonies
were counted manually. Each experiment was repeated a
minimum of 3 times.
Soft agar assay
Cells were treated or transfected as required. 60 mm dishes
were coated with a layer of 1% agarose (ThermoFisher
Scientific) in 2X DMEM (ThermoFisher Scientific) sup-
plemented with 20% FBS. 48 or 72 h post transfection, cells
were trypsinised and resuspended in 0.7% agarose in 2X
DMEM (ThermoFisher Scientific) supplemented with 20%
FBS at 1000 cells/mL. Once set, DMEM supplemented with
10% FBS and 50 U/mL penicillin was added. The plates
were then incubated for 14–21 days. Each experiment was
repeated at least three times. Visible colonies were counted
manually.
Annexin V assay
Annexin V apoptosis assay (TACS Annexin V kit; 4830-
250-K) was performed as indicated on the product data-
sheet. Briefly, cells seeded in 6 well plates were treated or
transfected as required. Cells were trypsinised and collected
by centrifugation. 1 × 106 cells were then incubated in
100 μL Annexin V reagent (10 μL 10 x binding buffer,
10 μL propidium iodide, 1 μL Annexin V-FITC (diluted 1 in
500) and 79 μL ddH2O) for 15 min at room temperature in
the dark. Samples were diluted in 1 × binding buffer before
analysis by flow cytometry. Samples were processed on a
CytoFLEX S flow cytometer (Beckman Coulter) and ana-
lysed using CytExpert (Beckman Coulter).
Statistical analysis
Data points from at least three individual, biological repeats
is shown in each graph. Unless otherwise indicated in the
figure legends, data was analysed using a two-tailed,
unpaired Student’s t-test and graphs were prepared using the
GraphPad Prism software (GraphPad, USA). Correlation
was determined using Spearman’s analysis. Error bars
represent the mean +/− standard deviation. Statistical sig-
nificance was determined as follows: *P < 0.05, **P < 0.01,
***P < 0.001.
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